Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Bright Minds Biosciences (DRUG), 3,523% surge in interest
• Rocket Pharmaceuticals (RCKT), 1,088% surge in interest
• Galapagos (GLPG), 395% surge in interest
• CorMedix (CRMD), 237% surge in interest
• Phathom Pharmaceuticals (PHAT), 214% surge in interest
• Elevai Labs (ELAB), 118% surge in interest
• Fulcrum Therapeutics (FULC), 93% surge in interest
• Oragenics (OGEN), 63% surge in interest

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. “Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin,” the company has stated.

Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company focused on advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s multi-platform approach allows the company to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

Galapagos is a global biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, the company synergizes science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is focused on commercializing its lead product DefenCath, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations.

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company has licensed the exclusive rights in the U.S., Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker. Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Elevai Labs specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. Driven by a commitment to scientific research, Elevai aims to transform personal health and beauty, the company states.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Oragenics is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. In October of 2023, Oragenics announced the signing of a definitive agreement with Odyssey Health to acquire assets related to their proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.

Recent news on these stocks:

August 28

Elevai Labs announced the filing of two innovative patents in collaboration with Yuva Biosciences. These patents support the development of Elevai’s innovative solutions for hair and scalp vitality. Patent Application Serial No 63/664,517, covers the unique and novel combination of Elevai exosomes and Y100, technologies that the inventors believe are synergistic and could allow significantly better results than either technology used alone. The second patent, Patent Application Serial No 63/664,526, covers the use of exosomes as a unique delivery system while also serving to protect and preserve the molecules being delivered.

Elevai Labs is poised to expand the application of their proprietary technologies beyond their current uses. This upcoming product line was recently announced as part of a conference presentation to medical aesthetics professionals by the inventors and scientific co-founders of Elevai Labs and Yuva Biosciences at The Aesthetic Show in Las Vegas, Jordan R. Plews, PhD and Keshav K. Singh, PhD, and the company plans to initiate full-scale marketing of the Elevai S-Series Root Renewal System in the near future. Given the demonstrated effectiveness of the underlying technologies, the S-Series is expected to attract keen interest from professional providers in the hair and scalp care market.

August 26

On Monday, Rodman & Renshaw analyst Brandon Folkes initiated coverage of CorMedix with a Buy rating and $13 price target.

August 23

Galapagos announced that the FDA has cleared Galapagos’ investigational new drug, or IND, application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma, or R/R NHL. GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produced using Galapagos’ innovative decentralized cell therapy manufacturing platform with the potential for the administration of fresh, fit cells within a median vein-to-vein time of seven days.

The primary objective of the Phase 1 part of ATALANTA-1 is to evaluate the safety and preliminary efficacy of GLPG5101 to determine the recommended dose for Phase 2. Secondary objectives include assessment of efficacy and feasibility of decentralized manufacturing of GLPG5101. The primary objective of the Phase 2 study is to evaluate the objective response rate. The secondary objectives include complete response rate, duration of response, progression free survival, overall survival, safety, pharmacokinetic profile, and the feasibility of decentralized manufacturing. Each enrolled patient will be followed for 24 months. The Phase 1/2 ATALANTA-1 study is currently ongoing in Europe, and early data have shown results in patients with R/R NHL.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.